Method and Timing Sample Clauses
The "Method and Timing" clause defines how and when specific actions or obligations under the contract must be performed. It typically outlines the required procedures, such as the format for delivering notices or the steps for submitting payments, and specifies deadlines or timeframes for these actions. By clearly establishing both the method and the timing for contractual duties, this clause helps prevent misunderstandings and disputes, ensuring that all parties are aware of their responsibilities and the schedule they must follow.
POPULAR SAMPLE Copied 2 times
Method and Timing. Payment of fees and other payments due to the Artist may be made in cash or certified cheque, company cheque or by electronic funds transfer. If fee payment is made by cheque, whether or not it is certified, such cheques must be available to the Artist on the day before the final banking day of the week. In the event that the day before the final banking day is a free day such cheques must be made available to the Artist on the day preceding the free day. Otherwise if the Artist is not called on the day before the final banking day, the Engager will endeavour to make such cheques available sooner. In the case of Artists whose company schedules do not reasonably permit them to pick up cheques, the cheques will be delivered in accordance with the above time frames, to the Artist at the place where the Artist is working.
Method and Timing. All payments under this Agreement must be made in immediately available and freely transferable funds. Each payment must be for value on the due date. All payments are to be made in US dollars.
Method and Timing. The Borrower shall make each payment due hereunder in one aggregate amount per calendar month, not later than 3:00 p.m. (New York City time) on the day when due, in lawful money of the United States of America (in freely transferable U.S. dollars and in immediately available funds), at such place or places identified by Lender by Electronic Transfer of Funds. BY WRITTEN NOTICE TO THE BORROWER, THE LENDER MAY REQUEST BORROWER TO MAKE SUCH PAYMENTS AT OTHER PLACES AND BY OTHER METHODS AND BORROWER SHALL THEREAFTER MAKE SUCH PAYMENTS IN ACCORDANCE WITH SUCH WRITTEN NOTICE FROM LENDER.
Method and Timing. All payments required to be made by the Ballet to the Artist shall be in legal tender of Canada. Payment of fees, and other payments and compensation may be made by direct deposit, in cash, by certified cheque or by company cheque. Artists shall be paid by the Ballet every two weeks during the engagement period. Such payments will be delivered to the Artist not later than 11:30 a.m. of the Thursday following the two week pay period and dated for the same date. Should a holiday or free day occur on a normally scheduled pay day, payment will be made not later than 11:30 a.m. of the immediately preceding working day.
Method and Timing. Imaging studies (CT or MRI) of the neck, chest, upper abdomen, and other anatomical region(s) of disease must be obtained at study Screening, Week 12, Week 18, and every 8 weeks thereafter until disease progression. Imaging studies will be completed at the End of Treatment visit for subjects who discontinue the study prematurely and have not had CT/MRI completed within the last 4 weeks (§6.5). For each subject, the same imaging method must be used at study screening and all follow-up assessments. RECIST v1.1 is primarily designed to evaluate the early effects of cytotoxic agents and depends on tumor shrinkage to demonstrate biologic activity. However, clinical evidence of tumor responses seen with immunotherapeutic agents, such as VTX-2337, can take longer to achieve and may occur after a period of disease stabilization or following an initial increase in tumor burden. In light of the limitations of utilizing RECIST v1.1 to evaluate immunomodulatory agents, immune-related response criteria have been proposed as an alternative to conventional RECIST to systematically detect the novel response patterns observed with immunologic agents.[1819] This study will use RECIST v1.1 for the baseline tumor evaluation, and an immune-related modification of RECIST v1.1 (irRECIST) to determine tumor response. As noted above, the immune-mediated responses expected from VTX-2337 require activation of the immune system prior to the observation of clinical responses, and such immune activation may take weeks to months to be clinically evident. Some subjects with advanced cancer may have objective increase of tumor burden within 12 weeks following the start of dosing on study. Such subjects may not have had sufficient time to develop the required immune activation or, in some subjects, tumor increases may represent infiltration of lymphocytes into the original tumor (often referred to as pseudo-progression). In traditional oncology studies, such increases in tumor burden during the first 12 weeks of the study would constitute progressive disease and lead to discontinuation of study treatment and imaging to detect response, thus disregarding the potential for subsequent immune-mediated clinical response. Therefore, in this study, the first imaging assessment will be performed at Week 12, followed by assessments at Week 18 and every 8 weeks thereafter. In addition, a key distinction between standard RECIST v1.1 criteria and irRECIST is that the latter requires early evidence o...